A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft tissue sarcoma.

被引：0
|
作者：
Huang, Xin
Ye, Zhaoming
Li, Tao
Wei, Yongzhong
Wang, Shoufeng
Liu, Yunxia
Chen, Jia
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[2] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[4] Nanjing Univ, Sch Med, Drum Tower Hosp, Nanjing, Peoples R China
[5] Hangzhou Third Hosp, Hangzhou, Peoples R China
[6] Nanjing Med Univ, Canc Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e23531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23531
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft-tissue sarcoma: Updated results.
    Li, Tao
    Ye, Zhaoming
    Wei, Yongzhong
    Wang, Shoufeng
    Liu, Yunxia
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A phase II study of epirubicin combined with anlotinib followed by anlotinib in the first-line treatment of advanced unresectablesoft tissue sarcoma.
    Zhou, Yuhong
    Wang, Zhiming
    Zhuang, Rongyuan
    Guo, Xi
    Zhang, Chenlu
    You, Yang
    Chen, Lisha
    Liu, Wenshuai
    Zhang, Yong
    Lu, Weiqi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Efficacy and safety of anlotinib combined with liposomal doxorubicin in first-line treatment of advanced soft-tissue sarcoma.
    Sun, Xin
    Guo, Wei
    Zhang, Ranxin
    Xie, Lu
    Xu, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Impact of chemotherapy on survival in locally advanced and metastatic soft tissue sarcoma.
    Ashamalla, Mark
    Yanagihara, Theodore
    Guirguis, Adel
    Ashamalla, Hani
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] First-Line Therapy for Metastatic Soft Tissue Sarcoma
    Meyer, Megan
    Seetharam, Mahesh
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (01)
  • [6] First-Line Therapy for Metastatic Soft Tissue Sarcoma
    Megan Meyer
    Mahesh Seetharam
    Current Treatment Options in Oncology, 2019, 20
  • [7] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [8] Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Phase I dose escalation results
    Zhou, Y.
    Feng, Y.
    Li, W.
    Zhuang, R.
    You, Y.
    Zhang, C.
    Wang, Z.
    Liu, W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1232 - S1232
  • [9] Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.
    Gelderblom, H.
    Blay, J.
    Seddon, B. M.
    Leahy, M.
    Ray-Coquard, I. L.
    De Brauwer, A.
    Veyt, E.
    Weitman, S. D.
    Hogendoorn, P. C.
    Hohenberger, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma.
    Deckert, PM
    Siehl, JM
    Thiel, E
    Schmittel, A
    Hütter, G
    Szelényi, H
    Keilholz, U
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 820S - 820S
12345